Industry Authority for 16 years

BPA Qualified Circulation

Loyal and Proven Readership

BioTech is in Our Genes

2003 MEDIA PLANNER CALENDARWWW.BIOPHARM-MAG.COM AND RATES INSIDE BioPharm International is the only peer-reviewed publication serving an audited audience of international science and business leaders involved in the utilization of biotechnology for the development and manufacture of therapeutics and diagnostics.

As the market leader for sixteen years, BioPharm International reaches over 90% of thebiotech and pharmaceutical companies with the highest investment in R&D, giving marketers direct access to the core buying

power of the biotech revolution. Publisher’s Own Data MARKET FACTS

R&D SPENDING

”With pipelines running dry and patents Estimated Global Pharmaceutical and Biotechnology R&D Spending, Total 1995-2002* on older drugs running out, today’s big (in $ billions) pharma is on the hunt for promising 72.9 80 products and looking to biotech to replenish 65.7 70 59.2 its pipeline. As such, R&D partnerships are 60 53.3 48 increasing and getting more financially 50 42 lucrative for biotech companies. 38.5 40.3 40 Venture capital investment continued 30 a downward trend in the second quarter 20 of 2002… 10 Life sciences companies, however, were 1995 1996 1997 1998 1999 2000 2001 2002 among the bright spots in this otherwise gloomy venture capital investing quarter. The biotech industry captured the Estimated Global Pharmaceutical and Biotechnology lions share of the life sciences VC funding. R&D Spending, By Category 1995-2002* Biotech companies, which raised $958 (in $ billions) million realised a strong 15 percent increase 80 in dollars invested compared with the first 70 quarter figure of $836 million.” 60 Other 50 —PricewaterhouseCoopers, 40 Clinical Evaluation by Tracy Letteroff, Global Manageing Partner, 30 Life Sciences Industry Services 20 Toxicology and Safety Testing

10 Drug Discovery

1995 1996 1997 1998 1999 2000 2001 2002

(Over)

* Source: Parexel, PhRMA, industry sources, Hambrecht and Quist estimates MARKET FACTS

BioPharm International delivers subscribers at the Biotech companies investing in R&D

R&D SPENDING AT SELECTED LEADING BIOTECHNOLOGY COMPANIES, 2000A — 2004E ($mm)

2000A 2001A 2002E 2003E 2004E BIOPHARM INT'L SUBSCRIBERS* Alexion 40.2 38.9 54.2 65.0 75.0 Yes 845.0 883.0 1,050.0 1,345.0 1,615.0 Yes 303.0 307.0 365.0 385.0 410.0 Yes Celera Genomics 166.7 207.7 145.9 220.0 250.0 Yes 71.7 84.2 134.0 140.0 170.0 Yes Chiron 299.0 344.0 356.0 390.0 430.0 Yes Corixa 41.9 138.6 133.1 137.7 144.6 Yes CV Therapeutics 40.8 81.2 102.0 110.0 125.0 Yes Exelexis 39.8 80.0 110.0 125.0 104.0 Yes GeneLogic 44.0 59.0 64.2 70.8 81.0 No 490.0 526.0 605.0 680.0 845.0 Yes Genzyme 104 190 212 228 246 Yes Human Genome Sciences 91.5 146.3 220.9 265.1 291.6 Yes ICOS 87.4 111.8 125.0 121.3 117.6 Yes Immunex 166.7 204.7 228.3 — — Yes Intrabiotics 39.2 37.7 24.2 28.8 37.4 Yes MedImmune 66.3 83.0 132.6 159.1 201.2 Yes Millennium Pharm. 269.0 401.0 502.0 519.0 540.0 Yes Protein Design Labs 42.3 52.1 57.3 63.0 75.6 Yes Scios 39.3 50.0 56.4 72.7 77.6 Yes Sequenom 19.2 29.3 33.1 40.5 47.0 Yes Transkaryotic Therapies 56.4 65.9 76.0 78.0 85.0 Yes Variagenics 23.2 16.9 22.0 26.4 35.7 Yes Vertex 85.0 148.7 210.0 245.7 — Yes Vical — 22.1 36.0 42.0 45.0 Yes

Totals 3,367.6 4,119.1 3,843.2 5,330.1 5,803.3

Source: Parexel, SG Cowen Biotechnology Quarterly, March 2002 * Publishers Own Data as of January 2003 CIRCULATION

CIRCULATION

BioPharm International delivers a targeted audience of professionals involved in all stages of development, scale-up and the manufacture of biopharmaceutical therapeutics and diagnostics.

EFFECTIVE JANUARY 2003, THE TOTAL AUDIENCE INCREASED TO 36,200 AROUND THE GLOBE*

25,000

10,000

1,200

United States Europe Canada

28,116 BPA QUALIFIED SUBSCRIBERS IN THE BUSINESSES AND FUNCTIONS YOU NEED TO REACH**

INDUSTRY Biopharmaceutical/Biotechnology/ Biologics/Classical Pharmaceutical/ Biodiagnostic Manufacturing/Research and Process Development, Biopharmaceutical/ Biotherapuetic Discovery, Development, 7.7% Contract Research/Analytical Services Formulation and Delivery 5.4% University/College/Research Institute 76.8% 2.6% Business/Investment/Legal Services 2.7% Specialty or Bulk Chemical Manufacturing 2.6% Architecture/Engineering Construction 2.1% Government 0.1% Others Allied to the Field

JOB FUNCTION

Quality Assurance/Control, Validation/ 25.2% Regulatory/Clinical Affairs

Research/Process/Analytical Development/ Technical Services/Support Corporate Management/Business Advisor 16.3% 39.6% Production/Manufacturing 10.4% Project Management 2.9% Plant/Project Engineering/Facility Design 3.7% Other 1.3% Lab Management 0.6% * Publisher’s Sworn Statement January 2003 ** BPA International Statement December 2002 CIRCULATION*

BioPharm International delivers subscribers at the top pharmaceutical, biopharmaceutical and biotech companies in the industry.

BIOPHARM INTERNATIONAL DELIVERS REACH AT THE INDUSTRY'S TOP COMPANIES* REACH 93 OF THE TOP 100 PUBLIC BIOTECH COMPANIES** # of subscribers

Abgenix Imclone 920 Immunex 793 Affymetrix Incyte Genomics GlaxoSmithKline 671 Alexion Pharma Inhale Therapeutics Johnson & Johnson 489 Abbott 485 Inc Insmed Merck 477 Alliance Pharmaceutical InterMune Aventis 471 Amgen IntraBiotics Eli Lilly 364 Amylin Invitrogen Bayer 360 Andrx Isis Pharmaceuticals 345 Aradigm Lexicon Genetics Amgen 331 Biogen Ligand Pharmaceuticals Hoffmann La Roche 330 BioMarin Pharmaceuticals Lion Bioscience Astra/Zeneca 293 BioPure Maxim Pharmaceuticals Schering Plough 276 Bristol-Myers Squibb 273 Biovail Maxygen Novartis 253 Caliper Medarex Akzo 210 Celera Genomics Medicines Genentech 174 Celgene Medimmune Genzyme 172 Cell Genesys Millennium Pharmaceuticals Boehringer Ingelheim 171 Cell Therapeutics Monsanto Sanofi 135 Celltech Myread Genetics Millipore 114 Cephalon Neurocrine Bioscience Cardinal Health 113 Cerus Neurogen Novo Nordisk 110 Biogen 106 Chiron NPS Pharmaceuticals Solvay 106 Corixa ONYX Pharmaceuticals Chiron 103 Cubist Orchid Bioscience Watson Pharmaceuticals 102 CuraGen OSI Pharm Apotex 92 CV Therapeutics Oxford GlycoScience 3M 86 Deltagen Pharmacopeia Elan Corp 84 Diversa Pharmacyclics Amersham 82 Elan Corp Portein Design Labs Becton Dickinson 81 Emisphere Technologies Praecis 80 Human Genome Sciences 73 Endo Regeneron Pharmaceuticals Dow 73 EntreMed Biopharm Ribozyme Alpharm 70 Exelexis Scios Nova Regeneron Pharmaceuticals 67 Genaissance Sepracor Medimmune 66 Genencor Shire Pharmaceuticals 65 Genentech SuperGen Lonza 65 Genome Therapeutics Symyx Technologies PPD INC 65 Targeted Genetics Proctor & Gamble 65 Genzyme Traskaryotic Ther. Fujisawa 62 Quintiles 62 Triangle Pharmaceuticals Ivax 61 Guilford Pharmaceutical Tularik IDEC 60 Human Genome Sciences Versicor DSM Catalytica 60 Hyseq Pharmaceuticals Vertex 58 ICOS ViroPharma 57 IDEC Xoma Schwarz 57 ILEX Oncology

* Publishers Own Data ** Parexel, Nature Biotechnology, June 2002 READERS

READER PROFILE RESULTS FROM A STUDY CONDUCTED BY SIGNET RESEARCH 2002 METHODOLOGY

OBJECTIVE The objective of this study was to determine reader buying influence and involvement with the publication, in addition to overall demographics.

SAMPLE The universe for the study is defined as 3,000 BioPharm subscribers. Instructions detailing how to draw the sample for this study were provided by Signet Research, Inc. to BioPharm.

SURVEY An email was broadcast on July 10, 2002 to a sample of 3,000 BioPharm subscribers asking them to click on a URL and participate in a survey. A second and third email were broadcast on July 18, 2002 and July 25, 2002, to non-respondents in an effort to encourage response. As an incentive, readers were offered a chance to win $250.

RESPONSE There were 998 undelivered and late returns so that the net effective mailing was 2,002. By the closing date of July 30, 2002, 491 returns had been received for a 25%* response rate.

* Response rate is a minimum calculated based on known undeliverables. True response rate may be higher due to an undetermined number of possible undeliverables, which current technology does not account for. BUSINESS AND FUNCTION

COMPANY’S PRIMARY BUSINESS 57.4% of the respondents are in manufacturing and development

Biopharmaceutical/Biologics Manufacturing 24.2% 16.5% University/College/Research Institute Classical Pharmaceutical Manufacturing 17.7% 9.2% Other Biopharmaceutical/ 6.9% 7.5% Contract Research Biologics Process Development and Analytical Services Biodiagnostic Manufacturing 3.7% 4.5% Architecture/Engineering/Construction (including Biodiagnostic Devices) 2.4% Government Specialty or Bulk Chemical Manufacturing 3.1% 1.2% No Response Biodiagnostic Process Development 1.8% 1.2% Business/Investment/Legal Services

RESPONSIBILITY OR FUNCTION 60% of respondents indicate they are involved in Research & Development and, of that, an average of 66% of their work is geared toward commercial product development

Research 28.1% 6.7% Technical Services/ Quality Assurance/Control/Validation 17.7% Analytical development/Support Process Development 8.6% 6.7% Project Management Production Manufacturing 8.1% 5.1% Corporate management 4.5% Other 4.3% Regulatory Affairs/ Clinical Affairs 3.1% No response 2.4% Plant Engineering/Design 1.2% Business Advisor 1.2% Materials Management/Purchasing 1.2% Project facility Engineering 1.0% Technology Transfer

JOB TITLES

Manager 15.5% 5.5% Engineer Research Scientist 13.0% 5.3% Senior Scientist Corporate Management 11.3% 5.1% Research Associate (CEO, COO, CTO, Owner, 4.9% Senior Specialist President, Executive Vice President) 3.9% Chemist Other 10.4% 3.5% Vice President Director 8.1% 2.6% Staff Scientist 2.4% No Response 2.4% Group Leader 1.6% Laboratory Manager 1.6% Supervisor 1.0% Section Manager 0.8% Research Director 0.8% Senior Analyst

Source: 2002 Readership Study conducted by Signet Research, Inc. LOYAL READERS

The BioPharm International audience consists of long-time readers who spend time with their issue. ¨ 74% READ 3 OR 4 OF 4 ISSUES

◊ 20% HAVE BEEN READERS READERS DON’T JUST READ BIOPHARM INTERNATIONAL — THEY RELY ON IT! FOR 5 YEARS OR LONGER For over 15 years, BioPharm International has been committed to providing its readers with reliable, timely and relevant information. „ ON AVERAGE, READERS SPEND 39 MINUTES READING Gives me information A TYPICAL ISSUE that helps me do my job better 70%

Identifies potential suppliers/resources 57%

Provides essential product information 40%

Gives me information that helps make purchasing decisions 21%

READERS WHO TAKE ACTION

Advertise in BioPharm International and reach a large audience of readers who take action. With a pass-along rate of 2 readers per copy and a circulation of 36,200*, you can reach over 108,000 potential customers.

95% OF RESPONDENTS TAKE ACTION AS A RESULT OF READING ADS OR ARTICLES

Filed for future reference 74%

Discussed article/advertisement with others 73%

Routed an article, ad or issue to another person 66%

Recommended the purchase of a product or service 42%

Incorporated a new technique 40%

Called or wrote for more information 33%

Purchased a product or service 28%

Source: 2002 Readership Study conducted by Signet Research, Inc. * Publisher’s Own Data READERS WITH BUYING POWER

57% OF RESPONDENTS ARE INVOLVED IN PURCHASING LABORATORY PRODUCTS & EQUIPMENT

Filtration Equipment/Apparatus 42%

Separation Equipment/Apparatus 37%

Purification Equipment/Apparatus 35%

Characterization Equipment/Apparatus 21%

Fermentors/Bioreactors 15%

Fill & Finish Equipment/Apparatus 15%

55% OF RESPONDENTS ARE INVOLVED IN PURCHASING BIOCHEMICALS/CHEMICALS/RAW MATERIALS

Media 28%

Enzymes 24%

Flourescent Immunoabsorbent Reagents 19%

Amino Acids/Nucleic Acids 18%

Cells/MABS 16%

OTHER AREAS OF PURCHASE INVOLVEMENT

Computer Systems 36%

Contract Consulting and Pharmaceutical Services 31%

Manufacturing Systems 22%

Controlled Environments 18%

Engineering and Facility Design Services 17%

Source: 2002 Readership Study conducted by Signet Research, Inc. READERS ENTRENCHED IN BIOPHARMACEUTICALS

Because BioPharm International readers are heavily entrenched in the development and manufacture of biopharmaceuticals, they are very interested in information on a variety of subjects.

BIOPHARM READERS ARE INTERESTED IN THE FOLLOWING SUBJECTS

Laboratory Equipment and Supplies 81% Regulatory 79% Validation 77% Filtration Products 68% Purified Water and Water for Injection 58% Biocontainment/Cleanrooms 58% Testing Services 57% Chromatography Equipment and Supplies 57% Media, Sera, Reagents 56% Cell Culture 53% Lyophilization 53% Enzymes 51% Contract Services 49% Bioreactors and Fermentors 46%

REACH AN UNTAPPED AUDIENCE

82% of respondents consider BioPharm International to be very or extremely reliable. 51% of respondents did NOT indicate that they receive or subscribe to ANY of these publications.

RECEIVE OR SUBSCRIBE TO:

Genetic Engineering News 24%

BioTechniques 22%

Contract Pharma 16%

BioProcessing 14%

Source: 2002 Readership Study conducted by Signet Research, Inc. ONLINE

WWW.BIOPHARM-MAG.COM

The Site for biopharmaceutical professionals

Meet our worldwide audience of biopharm professionals online, where click-thru capabilities allow you to bring these highly targeted prospects directly to the point of purchase. Users come to this Site for online access to the expert, peer-reviewed information that helps them bring biopharmaceutical therapeutics and diagnostics through all stages of development, scale-up and manufacturing.

MEET YOUR MARKET ONLINE WITH A BANNER, BUTTON OR SKYSCRAPER

ADVERTISING RATES AND SPECIFICATIONS

$1,000 per month BANNER 468 x 60 pixels 15-17 kb max file size ANIMATION: No limits on animation excluding anything that hampers the user experience FORMATS: .GIF, .JPG, .PNG

$1,000 per month SKYSCRAPER 120 x 600 pixels 35-38 kb max file size ANIMATION: No limits on animation excluding anything that hampers the user experience. FORMATS: .GIF, .JPG, .PNG

$500 per month BUTTONS 120 x 60 pixels 7-8 kb max file size ANIMATION: No limits on animation excluding anything that hampers the user experience. FORMATS: .GIF, .JPG, .PNG

Rich Media and Flash are also accepted. DISCOUNTS ARE AVAILABLE ON MULTIPLE BANNER BUYS MATERIALS SHOULD BE SENT TO: Contact your sales representative for more information [email protected] with clear instructions including positioning and run dates EDITORIAL & RATES

EDITORIAL ADVISORY BOARD In the opening days of the 21st century,

K.A. Ajit Simh the biopharmaceutical industry is a President, Shiba Associates Fredric G. Bader bewildering place to be: Biological Vice President, Process Sciences Centocor, Inc. Rory Budihandojo understanding of diseases and possible mechanisms for drugs IT Compliance Team Leader, GlaxoSmithKline is expanding at a dizzying pace. New tools and techniques for Edward G. Calamai Managing Parnter, Pharmaceutical Manufacturing and Compliance Associates, LLC biotech development and production are coming to light. John Carpenter Associate Professor, The industry itself, after years of R&D is poised to transform School of Pharmacy University of Colorado Health Sciences Center C. William Cherry itself through the introduction of dozens of new products. Vice President, QA and Regulatory Affairs, Aventis Bio-Services Inc. Suggy S. Chrai But business models to bring companies to profitability aren’t Principal Advisor, The Chrai Associates Janet Rose Christensen yet clear, investment capital is tight, and the FDA is on the President, QARA Services, LLC John Curling verge of sweeping changes in the way it regulates drugs and President, John Curling Consulting AB Rebecca Devine biologics. And the increasingly global nature of the business Biotechnology Consultant Mark D. Dibner is presenting a whole array of new challenges to the way President, BioAbility Howard Eisenberg companies produce and sell their products. Patent Attorney, Chernoff, Vilhauer, McClung & Stenzel, LLP Vipin K. Garg In a rapidly changing world, proven, practical information President and Chief Executive Officer, Tranzyme, Inc. Chris Holloway is the key to success. And in the world of biopharmaceuticals, Group Director of Regulatory Affairs, ERA Consulting Group Jean F. Huxsoll BioPharm International has been the source of that kind of Director, Quality Assurance, Bayer Corporation Barbara K. Immel information for 16 years. Each issue is packed with President, Immel Resources, LLC Steven S. Kuwahara peer-reviewed technical papers; news about companies, Director, Quality Control and Assay Development, Titan Pharmaceuticals Vincent H.L. Lee products, and people; advice on business strategy and Professor and Chairman, Pharmaceutical Sciences, University of Southern California management; and in-depth insight about markets, trends, Howard Levine President, BioProcess Technology Consultants and regulation. BioPharm International covers the whole range Laureen E. Little Editor, BioQuality and Senior Consultant, i2i Corporation of the biopharmaceutical development process including: Magda Marquet President and COO, Althea Technologies Drug Discovery/Preclinical Development Barbara Potts • Director of QC Biology, Genentech Investigational New Drug Applications Tom Pritchett • Senior Consultant, Quality Services Phase I and II Clinical Development Tom Ramsohoff • Senior Consultant, BioProcess Technology Consultants Phase III and IV Clinical Development Thomas G. Sanders • Vice President Business Development, MitoKor License Application Sally S. Seaver • President, Seave Associates Scale-Up Robert Seely • Process, Development Scientist, Amgen Colorado Manufacturing Alexander F. Sito • Vice President and General Manager Biosafety, MDS Pharma Sciences Logistics Thomas A. Smith • President, Biomedial Manufacturing Associates Whether their interest is laboratory technique, validation, Hans Jeurgen Spanier Product Manager, Process Filtration Sartorius AG, Biotechnology Division biosafety, quality assurance, separation & purification, Gail Sofer Director, Regulatory Services, BioReliance logistics, regulatory affairs, or industry developments, S. Joseph Tarnowski Vice President, Process and Product Development, ImClone Systems Inc. biopharmaceutical professionals will find the information William R. Tolbert President, WR Tolbert & Associates they need in BioPharm International. Authoritative, reliable, Krish Venkat Director, Analytical Services, Bristol-Myers Squibb readable, practical — it’s the tool professionals need in Gary Walsh Lecturer, Industrial Biochemistry, University of Limerick, Ireland today’s changing biopharmaceutical world. Lloyd Wolfinbarger President and Managing Partner, BioScience Consultants, LLC BIOPHARM EDITORIAL CALENDAR 2003 For 16 years, BioPharm has been the biopharmaceutical industry’s magazine of choice, providing authoritative, peer-reviewed, action-oriented information on every aspect of the industry, from science and technology to regulation and business issues. Today, as the industry undergoes a rapid evolution, BioPharm is evolving too, offering readers news from around the planet and hard-hitting business features about the events and issues shaping (and shaking) the industry, as well as the timely, trustworthy articles they’ve come to rely on. BioPharm International: The science, the business, the world of biopharmaceuticals.

ISSUE FOCUS SUPPLEMENT PRIMER BONUS DISTRIBUTION VALUE-ADDED OPPORTUNITIES

January Editorial Theme: Separation & Purification 21 CFR 11 WCBP FREE 4C Product/Literature Release Ad Close: December 9 Chromatography, Analytical Methods, Validation, Viral Clearance, Filtration & Centrifugation, Quick Start Program Scale-Up Issues, BioSafety Issues Special Focus: Analytical Advances

February Editorial Theme: Contract Services/Outsourcing WilBio Baculovirus & Insect Cell Culture FREE Advertiser Profile Ad Close: January 6 Technology Transfer Issues, Project Management, Facility Resource Management Auditing, Contractors Informex and Subcontractors, Regulatory Approaches, Preparing for Inspections ASME

March Editorial Theme: Validation BioPharm Guide to Pittcon FREE Advertiser Profile Ad Close: February 3 Assay Development, Downstream Processing, Computer Systems & Automation, Fermentation & Cell Culture: PDA Spring Literature Pack at Interphex and PDA Spring Analytical Methods Development, Viral Inactivation/Clearance A Closer Look Interphex

April Editorial Theme: Quality/GMP Issues WilBio Waterside Conference FREE 4C Product/Literature Release Ad Close: March 3 CGMP Issues, Validation, Environmental Monitoring (Contamination Control), Quality Issues, QA/QC WilBio FDA Science Forum

May Editorial Theme: Fermentation & Cell Culture Sofer Series: WilBio Transgenics BioProcessing FREE 4C Product/Literature Release Ad Close: April 1 Cell Banking, Cell Line Characterization, Contract Manufacturing, Process Control and Automation, Viral Inactivation ASM Scale-Up Strategies, Transgenics, Validation, CGMPs, QA/QC Achema Special Focus: Analytical Advances

June Editorial Theme: Executive Focus BIO 2003 FREE 4C Product/Literature Release Ad Close: May 1 WilBio Raw Materials & Contract Services Literature Pack at Bio 2003

July Editorial Theme: Contract Services/Outsourcing BioPharm Guide to Columns FREE 4C Product/Literature Release Ad Close: June 2 Technology Transfer Issues, Project Management, Facility Resource Management Auditing, Contractors and Subcontractors, Regulatory Approaches, Preparing for Inspections Special Focus: Analytical Advances

August Editorial Theme: Quality/GMP Issues WilBio Cell & Tissue FREE Ad Perfomance Study Ad Close: July 7 CGMP Issues, Validation, Environmental Monitoring (Contamination Control), Quality Issues, QA/QC Special Focus: Analytical Advances

September Editorial Theme: Separation & Purification BioPharm Guide to Selecting ACS Fall FREE 1/3 Page, Advertiser Profile Ad Close: August 1 Chromatography, Analytical Methods, Validation, Viral Clearance, Filtration & Centrifugation, and Working with a CMO BioTechniqua Autumn Advertising Package Scale-Up Issues, BioSafety Issues

October Editorial Theme: Validation RAPS FREE 1/3 Page, Advertiser Profile Ad Close: September 1 Assay Development, Downstream Processing, Computer Systems & Automation, CPhi Autumn Advertising Package Analytical Methods Development, Viral Inactivation/Clearance Literature Pack at RAPS Special Focus: Analytical Advances

November Editorial Theme: Fermentation & Cell Culture Survival Guide to AAPS FREE 4C Product/Literature Release Ad Close: October 1 Cell Banking, Cell Line Characterization, Contract Manufacturing, Process Control and Automation, an FDA Inspection PDA Fall Literature Pack at AAPS and PDA Fall Scale-Up Strategies, Transgenics, Validation, CGMPs, QA/QC Special Focus: Analytical Advances

December Forecast: A look forward at the most important products, technologies, industry issues of Bonus Distritbution Ad Close: November 3 2004 as well as Corporate Capabilities Profiles and a Salary Survey. at select 2004 shows 2003 FOUR COLOR GROSS RATES — US DOLLARS/EURO

1X 3X 6X 12X 18X 24X Full Page 7,065 6,705 6,565 6,255 6,105 6,000 2/3 Page 5,930 5,690 5,610 5,415 5,305 5,210 1/2 Page 5,595 5,325 5,220 5,005 4,885 4,815 1/3 Page 4,375 4,225 4,165 3,990 3,955 3,925 1/4 Page 3,740 3,630 3,575 3,440 3,440 3,385

SPECIAL POSITIONS — ADD TO FOUR COLOR RATES

Cover 2 575 Cover 3 575 Cover 4 750 Preferred Pos. 450

2003 FOUR COLOR GROSS RATES — UK STERLING

1X 3X 6X 12X 18X 24X Full Page 4,560 4,325 4,235 4,035 3,940 3,870 2/3 Page 3,825 3,675 3,620 3,495 3,425 3,365 1/2 Page 3,610 3,435 3,370 3,230 3,155 3,110 1/3 Page 2,825 2,730 2,690 2,575 2,555 2,535 1/4 Page 2,415 2,345 2,310 2,255 2,220 2,185

SPECIAL POSITIONS — ADD TO FOUR COLOR RATES

Cover 2 375 Cover 3 375 Cover 4 485 Preferred Pos. 295

PRODUCTION REQUIREMENTS AD DIMENSIONS WIDTH WIDTH DEPTH DEPTH Full Page 7” 177 mm 10” 254 mm Digital data is required for all ad submissions. Preferred format is PDF X/1a. Acceptable formats are PDF and TIFF/IT-p1. Any ads supplied in 2/3 Page 4 9/16” 115 mm 10” 254 mm non-preferred or non-acceptable formats, such as native application 1/2 Page Island 4 9/16” 115 mm 7 1/2” 190 mm files, will be charged a $150 processing fee. We cannot guarantee 1/2 Page Horizontal 7” 177 mm 4 7/8” 123 mm the accuracy of reproduction from any ads supplied in non-preferred or non-acceptable formats, and will not issue any make goods. All 1/2 Page Vertical 3 3/8” 85 mm 10” 254 mm supplied film will be copy dot scanned and will incur a $50 scanning 1/3 Page Square 4 9/16” 115 mm 4 7/8” 123 mm fee. For detailed instructions, contact the production manager or 1/3 Page Vertical 2 3/16” 55 mm 10” 254 mm download digital ad specifications from the Advanstar.com home page at www.Advanstar.com. A SWOP certified color proof MUST 1/4 Page 3 3/8” 85 mm 4 7/8” 123 mm be forwarded with the digital ad file. If we do not receive a SWOP certified proof, we cannot guarantee the accuracy of the reproduction WIDTH WIDTH and will not issue any make goods. Trim Size 8” x 10 3/4” 203 mm x 273 mm Send all materials and ad insertion orders to: Bleed 8 1/4” x 11” 210 mm x 279 mm Karen Lenzen, BioPharm, Live Matter 7” x 10” 177 mm x 254 mm 131 West 1st Street, Duluth, MN 55802-2065, USA Spread Size 15” x 10” 381 mm x 254 mm Tel: 1-218-723-9371 • Fax: 1-218-723-9576 • Email: [email protected] Bleed (Spread) 16 1/2” x 11” 419 mm x 279 mm SPECIAL ISSUES

SUPPLEMENTS

21 CFR PART 11 Published in January Perhaps the most urgent issue facing the biotech industry today is compliance with the FDA’s rule on data integrity and electronic signatures, known as 21 CFR Part 11. BioPharm International’s special supplement on the issue brings together the expertise of leading companies and the consultants they work with to explain how to organize and manage a Part 11 remediation and how to take advantage of the cost savings implicit in all-electronic regulatory filings.

VIRAL INACTIVATION Published in May One of the most well-read series in the BioPharm International’s history has been consultant Gail Sofer’s far-reaching, authoritative review of the scientific literature of viral inactivation — must-read, must-keep information for any biopharmaceutical professional. Now the whole Sofer series, along with several never-before-published chapters are collected in stand-alone form.

SURVIVAL GUIDE TO AN FDA INSPECTION Published in November This authoritative guide explains how to manage every phase of an FDA inspection. Readers will learn the most practical steps they can take to prepare for an imminent inspection, how staff members should interact with inspectors, and how to follow up after the FDA has come and gone. Plus: up-to-the-minute guidance on how current changes at the FDA will affect future inspections.

PRIMERS

BioPharm International’s primers present basic issues of biotechnology in language anyone can understand. Designed as a tool for communications and training, and created with the assistance of industry professionals, vendors, and academic experts, they’ve evolved into some of BioPharm International’s most popular editorial products.

BIOPHARM INTERNATIONAL’S GUIDE TO FERMENTATION & CELL CULTURE Published in March One of the most popular titles in the primer series returns in a second, fully updated edition. Biotech’s most basic production technique is explained in simple, straightforward terms. The primer also includes a glossary, references, and a guide to online resources.

BIOPHARM INTERNATIONAL’S GUIDE TO COLUMNS Published in July One of the most widely used techniques in biotech production (and one of the least understood by nonspecialists) is chromatography. This all-new primer dispels the mystery, explaining how chromatography works and how it is used in both analysis and bioproduction.

BIOPHARM INTERNATIONAL’S GUIDE TO SELECTING AND WORKING WITH A CMO Published in September Our first primer on the business side of biopharmaceuticals contains a complete guide to contract manufacturing organizations. What are CMOs? What benefits do they offer biopharmaceutical companies? What are the key steps companies should take to truly benefit by using CMO’s? The primer covers all this and more. THE ADVANSTAR ADVANTAGE

THE PHARMACEUTICAL BUSINESS IS INCREDIBLY COMPLEX.

REACHING EVERY PART OF IT DOESN'T HAVE TO BE.

If you want the #1 way to reach key decision-makers in every area of the pharmaceutical business, the Advanstar Pharmaceutical and Science Group is your only choice. Whether it’s discovery, development, clinical trials, manufacturing, even sales and marketing, we're the only family of publications that cover every aspect of the industry value chain. Better yet, we’re the dominant publication in each of those areas with all our circulation audited by BPA. Remember, if you want your marketing plans to succeed, just keep it in the family: the Advanstar Pharmaceutical & Science Group.